These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 35723411)

  • 1. Virologic and Immunologic Characterization of Coronavirus Disease 2019 Recrudescence After Nirmatrelvir/Ritonavir Treatment.
    Carlin AF; Clark AE; Chaillon A; Garretson AF; Bray W; Porrachia M; Santos AT; Rana TM; Smith DM
    Clin Infect Dis; 2023 Feb; 76(3):e530-e532. PubMed ID: 35723411
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical, Virologic, and Immunologic Evaluation of Symptomatic Coronavirus Disease 2019 Rebound Following Nirmatrelvir/Ritonavir Treatment.
    Epling BP; Rocco JM; Boswell KL; Laidlaw E; Galindo F; Kellogg A; Das S; Roder A; Ghedin E; Kreitman A; Dewar RL; Kelly SEM; Kalish H; Rehman T; Highbarger J; Rupert A; Kocher G; Holbrook MR; Lisco A; Manion M; Koup RA; Sereti I
    Clin Infect Dis; 2023 Feb; 76(4):573-581. PubMed ID: 36200701
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Virologic and Immunologic Characterization of COVID-19 Recrudescence after Nirmatrelvir/Ritonavir Treatment.
    Carlin AF; Clark AE; Chaillon A; Garretson AF; Bray W; Porrachi M; Santos AT; Smith DM
    Res Sq; 2022 May; ():. PubMed ID: 35611335
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of nirmatrelvir-ritonavir on viral clearance and length of hospital stay in patients infected with SARS-CoV-2 omicron variants.
    Wang Y; Zhao D; Chen X; Liu X; Xiao W; Feng L
    Influenza Other Respir Viruses; 2023 Feb; 17(2):e13095. PubMed ID: 36843224
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molnupiravir and Nirmatrelvir-Ritonavir: Oral Coronavirus Disease 2019 Antiviral Drugs.
    Saravolatz LD; Depcinski S; Sharma M
    Clin Infect Dis; 2023 Jan; 76(1):165-171. PubMed ID: 35245942
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-world effectiveness of molnupiravir and nirmatrelvir plus ritonavir against mortality, hospitalisation, and in-hospital outcomes among community-dwelling, ambulatory patients with confirmed SARS-CoV-2 infection during the omicron wave in Hong Kong: an observational study.
    Wong CKH; Au ICH; Lau KTK; Lau EHY; Cowling BJ; Leung GM
    Lancet; 2022 Oct; 400(10359):1213-1222. PubMed ID: 36216007
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world effectiveness of early molnupiravir or nirmatrelvir-ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission during Hong Kong's omicron BA.2 wave: a retrospective cohort study.
    Wong CKH; Au ICH; Lau KTK; Lau EHY; Cowling BJ; Leung GM
    Lancet Infect Dis; 2022 Dec; 22(12):1681-1693. PubMed ID: 36029795
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nirmatrelvir-ritonavir therapy and COVID-19 vaccination improve clinical outcomes of SARS-CoV-2 Omicron variant infection.
    Qi T; Jin Y; Wang H; Liao Y; Liu T; Mao E; Li F; Li Y; Fan X; Ling Y
    J Med Virol; 2023 Feb; 95(2):e28497. PubMed ID: 36651302
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparable Outcomes for Bebtelovimab and Ritonavir-Boosted Nirmatrelvir Treatment in High-Risk Patients With Coronavirus Disease-2019 During Severe Acute Respiratory Syndrome Coronavirus 2 BA.2 Omicron Epoch.
    Razonable RR; O'Horo JC; Hanson SN; Arndt RF; Speicher LL; Seville TA; Hall ST; Pike ML; Heyliger A; Larsen JJ; Ganesh R; Tulledge-Scheitel SM
    J Infect Dis; 2022 Nov; 226(10):1683-1687. PubMed ID: 36124696
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molnupiravir and Nirmatrelvir/Ritonavir: The New Available Antiviral Options for COVID-19.
    Sutanto ST; Sinto R; Pasaribu A; Shakinah S
    Acta Med Indones; 2022 Oct; 54(4):638-644. PubMed ID: 36624705
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Coronavirus disease 2019 rebounds following nirmatrelvir/ritonavir treatment.
    Lai CC; Hsueh PR
    J Med Virol; 2023 Feb; 95(2):e28430. PubMed ID: 36571273
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of Nirmatrelvir/Ritonavir Treatment on Upper Respiratory Severe Acute Respiratory Syndrome Coronavirus 2 Reverse Transcription-Polymerase Chain Reaction (SARS-Cov-2 RT-PCR) Negative Conversion Rates Among High-Risk Patients With Coronavirus Disease 2019 (COVID-19).
    Li H; Gao M; You H; Zhang P; Pan Y; Li N; Qin L; Wang H; Li D; Li Y; Qiao H; Gu L; Xu S; Guo W; Wang N; Liu C; Gao P; Niu J; Cao J; Zheng Y
    Clin Infect Dis; 2023 Feb; 76(3):e148-e154. PubMed ID: 35870128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. VV116 versus Nirmatrelvir-Ritonavir for Oral Treatment of Covid-19.
    Cao Z; Gao W; Bao H; Feng H; Mei S; Chen P; Gao Y; Cui Z; Zhang Q; Meng X; Gui H; Wang W; Jiang Y; Song Z; Shi Y; Sun J; Zhang Y; Xie Q; Xu Y; Ning G; Gao Y; Zhao R
    N Engl J Med; 2023 Feb; 388(5):406-417. PubMed ID: 36577095
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-world use of nirmatrelvir-ritonavir in outpatients with COVID-19 during the era of omicron variants including BA.4 and BA.5 in Colorado, USA: a retrospective cohort study.
    Aggarwal NR; Molina KC; Beaty LE; Bennett TD; Carlson NE; Mayer DA; Peers JL; Russell S; Wynia MK; Ginde AA
    Lancet Infect Dis; 2023 Jun; 23(6):696-705. PubMed ID: 36780912
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nirmatrelvir/ritonavir treatment in SARS-CoV-2 positive kidney transplant recipients - a case series with four patients.
    Schneider J; Wobser R; Kühn W; Wagner D; Tanriver Y; Walz G
    BMC Nephrol; 2023 Apr; 24(1):99. PubMed ID: 37061677
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of Oral Antivirals Ritonavir-Nirmatrelvir and Molnupiravir in Patients with Multiple Myeloma Is Associated with Low Rates of Severe COVID-19: A Single-Center, Prospective Study.
    Spiliopoulou V; Ntanasis-Stathopoulos I; Malandrakis P; Gavriatopoulou M; Theodorakakou F; Fotiou D; Migkou M; Roussou M; Eleutherakis-Papaiakovou E; Kastritis E; Dimopoulos MA; Terpos E
    Viruses; 2023 Mar; 15(3):. PubMed ID: 36992413
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The efficacy of Paxlovid against COVID-19 is the result of the tight molecular docking between M
    Dawood AA
    Adv Med Sci; 2023 Mar; 68(1):1-9. PubMed ID: 36368287
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Short-Term Effectiveness of Oral Nirmatrelvir/Ritonavir Against the SARS-CoV-2 Omicron Variant and Culture-Positive Viral Shedding.
    Lee E; Park S; Choi JP; Kim MK; Yang E; Ham SY; Lee S; Lee B; Yang JS; Park BK; Kim DS; Lee SY; Lee JY; Jang HC; Jeon J; Park SW
    J Korean Med Sci; 2023 Feb; 38(8):e59. PubMed ID: 36852855
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Antiviral Effect of Nirmatrelvir/Ritonavir during COVID-19 Pandemic Real-World Data.
    Petrakis V; Rafailidis P; Trypsianis G; Papazoglou D; Panagopoulos P
    Viruses; 2023 Apr; 15(4):. PubMed ID: 37112956
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nirmatrelvir Plus Ritonavir: First Approval.
    Lamb YN
    Drugs; 2022 Apr; 82(5):585-591. PubMed ID: 35305258
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.